C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.53 +2.06%

+$0.08 today

Market cap
$332.23M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.84M

Average 2.76M

CCCC EBITDA Margin

EBITDA as a percentage of revenue.

C4 Therapeutics, Inc.NASDAQ: CCCC

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to -379.2%

EBITDA Margin was -379.2% in Q1 FY2026, down 21.8 pp from a year earlier. On a trailing-twelve-month basis it was -287.9%, down 44.6 pp year over year. Over 3 fiscal years it widened by 113.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -216.4% for the fiscal year ending Dec 2026, up from -286.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-379.2%-198.2 pp QoQ
Last fiscal yearDec 2025
-286.3%+4.2 pp YoY
LTMMar 2026
-287.9%-44.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-21.8 pp-369.8 pp-348.0 pp
1 year+4.2 pp+69.9 pp+65.7 pp
3 years+113.4 pp-150.4 pp-263.7 pp
5 years+308.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-286.3%
Year-over-year change
+4.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CCCC compares with its peers on the latest reported figures

  • CCCC's LTM Mar 2026 EBITDA Margin of -287.9% is the 3rd highest of the 7 companies compared; the peer median is -1334.7%.
  • Its year-over-year change of -44.6 pp is the 3rd highest of 6, against a peer median of -229.0 pp.
  • Over three fiscal years its change of +113.4 pp compares with a peer median of -178.5 pp.
CCCC Competitors Peer median
EBITDA Margin for CCCC and competitors
Company Period LTM level YoY 3-year change
CDXSCodexis, Inc.LTM Mar 2026-28.2% +91.2 pp-29.1 pp
OABIOmniAb, Inc.LTM Mar 2026-117.0% +50.4 pp-225.4 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-339.9% -229.0 pp-131.5 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026-2329.5% -862.2 pp+207.6 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3439.7% —-2679.5 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026-8872.8% -9159.7 pp-2521.0 pp
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
Peer median (excluding CCCC) -1334.7%-229.0 pp-178.5 pp

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.79M31.1M20.76M35.58M35.95M
Cost of Revenue007.74M07.98M
Gross Profit45.79M31.1M13.02M35.58M27.97M
Gross Margin100.0%100.0%62.7%100.0%77.8%
Research & Development94.67M117.84M117.71M110.64M104.24M
Selling, General & Admin33.25M42.79M42.08M42.12M36.2M
Operating Expenses127.92M160.63M152.05M155.2M132.46M
Depreciation & Amortization1.49M1.68M7.74M1.82M1.96M
EBITDA(80.26M)(124.28M)(122.1M)(103.37M)(102.91M)
EBITDA Margin-175.3%-399.7%-588.3%-290.5%-286.3%
Operating Income(82.13M)(129.53M)(139.03M)(119.61M)(104.49M)
Operating Margin-179.4%-416.6%-669.8%-336.1%-290.7%
Interest Income387K3.58M9.81M14.43M10.35M
Interest Expense2.15M2.22M1.37M00
Other Income / Expenses(1.76M)1.36M7.82M14.43M(384K)
Income Before Tax(83.89M)(128.18M)(131.21M)(105.19M)(104.87M)
Pre-Tax Margin-183.2%-412.2%-632.2%-295.6%-291.7%
Income Tax Expense001.28M131K121K
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Net Margin-183.2%-412.2%-638.3%-296.0%-292.1%
EPS (Basic)(1.82)(2.62)(2.67)(1.52)(1.27)
EPS (Diluted)(1.82)(2.62)(2.67)(1.52)(1.27)
Weighted Avg Shares46.04M48.86M49.64M69.37M82.89M
Weighted Avg Shares (Diluted)46.04M48.86M49.64M69.37M82.89M

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.